Download PDF
Semin Thromb Hemost 2017; 43(04): 386-396
DOI: 10.1055/s-0037-1599153
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Point-of-Care Coagulation Testing in Cardiac Surgery

Daniel Bolliger
1   Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland
,
Kenichi A. Tanaka
2   Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, University of Maryland, Baltimore, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
30 March 2017 (online)

    Permissions and Reprints

Abstract

Bleeding complications after cardiac surgery are common and are associated with increased morbidity and mortality. Their etiology is multifactorial, and treatment decisions are time sensitive. Point-of-care (POC) testing has an advantage over standard laboratory tests for faster turn-around times, and timely decision on coagulation intervention(s). The most common POC coagulation testing is the activated clotting time (ACT), used to monitor heparin therapy while on cardiopulmonary bypass. Viscoelastic coagulation tests including thromboelastometry (ROTEM) and thromboelastography (TEG) have been recommended for the treatment of postoperative bleeding after cardiac surgery because the ROTEM/TEG-guided treatment algorithms reduced the use of blood products. Other POC tests are commercially available, but there is sparse evidence for their routine use in cardiac surgery. These devices include heparin management systems, POC prothrombin time and activated partial thromboplastin time, POC fibrinogen assay, and whole blood platelet function tests. There are multiple confounding elements and conditions associated with cardiac surgery, which can significantly alter test results. Anemia and thrombocytopenia are regularly associated with deviations in many POC devices. In summary, POC coagulation testing allows for rapid clinical decisions in hematological interventions, and, when used in conjunction with a proper transfusion algorithm, may reduce blood product usage, and potentially complications associated with blood transfusion.

Keywords

blood coagulation tests - point-of-care systems - cardiac surgery
 

  • References

  • 1 Vivacqua A, Koch CG, Yousuf AM. , et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both?. Ann Thorac Surg 2011; 91 (06) 1780-1790
    CrossrefPubMedGoogle Scholar
  • 2 Tackett SM, Calcaterra D, Magee G, Lattouf OM. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothorac Vasc Anesth 2014; 28 (06) 1558-1565
    CrossrefPubMedGoogle Scholar
  • 3 Scott BH, Seifert FC, Grimson R. Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth 2008; 11 (01) 15-19
    CrossrefPubMedGoogle Scholar
  • 4 Koch CG, Li L, Duncan AI. , et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34 (06) 1608-1616
    CrossrefPubMedGoogle Scholar
  • 5 Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116 (22) 2544-2552
    CrossrefPubMedGoogle Scholar
  • 6 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
    CrossrefPubMedGoogle Scholar
  • 7 Ozier Y, Hunt BJ. Against: Fibrinogen concentrate for management of bleeding: against indiscriminate use. J Thromb Haemost 2011; 9 (01) 6-8
    CrossrefPubMedGoogle Scholar
  • 8 Cappabianca G, Mariscalco G, Biancari F. , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care 2016; 20: 5
    PubMedGoogle Scholar
  • 9 Haas T, Fries D, Tanaka KA, Asmis L, Curry NS, Schöchl H. Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: is there any evidence?. Br J Anaesth 2015; 114 (02) 217-224
    CrossrefPubMedGoogle Scholar
  • 10 Kozek-Langenecker SA, Afshari A, Albaladejo P. , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30 (06) 270-382
    CrossrefPubMedGoogle Scholar
  • 11 Bolliger D, Tanaka KA. Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev 2013; 27 (04) 213-220
    CrossrefPubMedGoogle Scholar
  • 12 Rahe-Meyer N, Levy JH, Mazer CD. , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 2016; 117 (01) 41-51
    CrossrefPubMedGoogle Scholar
  • 13 Christensen MC, Dziewior F, Kempel A, von Heymann C. Increased chest tube drainage is independently associated with adverse outcome after cardiac surgery. J Cardiothorac Vasc Anesth 2012; 26 (01) 46-51
    CrossrefPubMedGoogle Scholar
  • 14 Whitlock R, Crowther MA, Ng HJ. Bleeding in cardiac surgery: its prevention and treatment--an evidence-based review. Crit Care Clin 2005; 21 (03) 589-610
    CrossrefPubMedGoogle Scholar
  • 15 Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004; 78 (02) 527-534 , discussion 534
    CrossrefPubMedGoogle Scholar
  • 16 Mehta RH, Sheng S, O'Brien SM. , et al; Society of Thoracic Surgeons National Cardiac Surgery Database Investigators. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes 2009; 2 (06) 583-590
    CrossrefPubMedGoogle Scholar
  • 17 Bolliger D, Mauermann E, Tanaka KA. Thresholds for perioperative administration of hemostatic blood components and coagulation factor concentrates: An unmet medical need. J Cardiothorac Vasc Anesth 2015; 29 (03) 768-776
    CrossrefPubMedGoogle Scholar
  • 18 Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002; 74 (04) 1180-1186
    CrossrefPubMedGoogle Scholar
  • 19 Karkouti K, Wijeysundera DN, Yau TM. , et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44 (10) 1453-1462
    CrossrefPubMedGoogle Scholar
  • 20 Weber CF, Klages M, Zacharowski K. Perioperative coagulation management during cardiac surgery. Curr Opin Anaesthesiol 2013; 26 (01) 60-64
    CrossrefPubMedGoogle Scholar
  • 21 Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113 (05) 1205-1219
    CrossrefPubMedGoogle Scholar
  • 22 Ternström L, Radulovic V, Karlsson M. , et al. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res 2010; 126 (02) e128-e133
    CrossrefPubMedGoogle Scholar
  • 23 Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg 2008; 106 (03) 713-718
    CrossrefPubMedGoogle Scholar
  • 24 Weber CF, Görlinger K, Meininger D. , et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117 (03) 531-547
    CrossrefPubMedGoogle Scholar
  • 25 Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003; 138 (03) W15-24
    CrossrefPubMedGoogle Scholar
  • 26 Toulon P, Ozier Y, Ankri A, Fléron MH, Leroux G, Samama CM. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost 2009; 101 (02) 394-401
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Gravlee GP, Arora S, Lavender SW. , et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994; 58 (01) 216-221
    CrossrefPubMedGoogle Scholar
  • 28 Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15 (05) R239
    CrossrefPubMedGoogle Scholar
  • 29 O'Shaughnessy DF, Atterbury C, Bolton Maggs P. , et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (01) 11-28
    CrossrefPubMedGoogle Scholar
  • 30 Dempfle CE, Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008; 34 (05) 445-450
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Guzzetta NA, Amin SJ, Tosone AK, Miller BE. Change in heparin potency and effects on the activated clotting time in children undergoing cardiopulmonary bypass. Anesth Analg 2012; 115 (04) 921-924
    CrossrefPubMedGoogle Scholar
  • 32 Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90 (05) 1076-1079
    CrossrefPubMedGoogle Scholar
  • 33 Levy JH, Sniecinski RM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years?. Anesth Analg 2010; 111 (04) 833-835
    CrossrefPubMedGoogle Scholar
  • 34 Yamamoto T, Wolf HG, Sinzobahamvya N, Asfour B, Hraska V, Schindler E. Prolonged activated clotting time after protamine administration does not indicate residual heparinization after cardiopulmonary bypass in pediatric open heart surgery. Thorac Cardiovasc Surg 2015; 63 (05) 397-403
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87 (04) 781-785
    PubMedGoogle Scholar
  • 36 Bischof DB, Ganter MT, Shore-Lesserson L. , et al. Viscoelastic blood coagulation measurement with Sonoclot predicts postoperative bleeding in cardiac surgery after heparin reversal. J Cardiothorac Vasc Anesth 2015; 29 (03) 715-722
    CrossrefPubMedGoogle Scholar
  • 37 Cotton BA, Faz G, Hatch QM. , et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma 2011; 71 (02) 407-414 , discussion 414–417
    CrossrefPubMedGoogle Scholar
  • 38 Vonk AB, Veerhoek D, van den Brom CE, van Barneveld LJ, Boer C. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28 (02) 235-241
    CrossrefPubMedGoogle Scholar
  • 39 Koster A, Fischer T, Praus M. , et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97 (04) 837-841
    CrossrefPubMedGoogle Scholar
  • 40 Aziz KA, Masood O, Hoschtitzky JA, Ronald A. Does use of the Hepcon point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery?. Interact Cardiovasc Thorac Surg 2006; 5 (04) 469-482
    CrossrefPubMedGoogle Scholar
  • 41 Despotis GJ, Joist JH, Hogue Jr CW. , et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76 (06) 902-908
    PubMedGoogle Scholar
  • 42 Despotis GJ, Joist JH, Hogue Jr CW. , et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110 (01) 46-54
    CrossrefPubMedGoogle Scholar
  • 43 Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010; 111 (04) 849-855
    CrossrefPubMedGoogle Scholar
  • 44 Radulovic V, Laffin A, Hansson KM, Backlund E, Baghaei F, Jeppsson A. Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study. PLoS One 2015; 10 (07) e0130271
    CrossrefPubMedGoogle Scholar
  • 45 Guzzetta NA, Bajaj T, Fazlollah T. , et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008; 106 (02) 419-425
    CrossrefPubMedGoogle Scholar
  • 46 Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg 2010; 111 (01) 173-179
    CrossrefPubMedGoogle Scholar
  • 47 Chandler WL, Ferrell C, Trimble S, Moody S. Development of a rapid emergency hemorrhage panel. Transfusion 2010; 50 (12) 2547-2552
    CrossrefPubMedGoogle Scholar
  • 48 Chavez JJ, Weatherall JS, Strevels SM, Liu F, Snider CC, Carroll RC. Evaluation of a point-of-care coagulation analyzer on patients undergoing cardiopulmonary bypass surgery. J Clin Anesth 2004; 16 (01) 7-10
    CrossrefPubMedGoogle Scholar
  • 49 Choi TS, Greilich PE, Shi C, Wilson JS, Keller A, Kroll MH. Point-of-care testing for prothrombin time, but not activated partial thromboplastin time, correlates with laboratory methods in patients receiving aprotinin or epsilon-aminocaproic acid while undergoing cardiac surgery. Am J Clin Pathol 2002; 117 (01) 74-78
    CrossrefPubMedGoogle Scholar
  • 50 Meesters MI, Kuiper G, Vonk AB, Loer SA, Boer C. Validation of a point-of-care prothrombin time test after cardiopulmonary bypass in cardiac surgery. Anaesthesia 2016; 71 (10) 1163-1168
    CrossrefPubMedGoogle Scholar
  • 51 Davenport R, Manson J, De'Ath H. , et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med 2011; 39 (12) 2652-2658
    CrossrefPubMedGoogle Scholar
  • 52 Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; 18 (05) 269-276
    CrossrefPubMedGoogle Scholar
  • 53 Gauss T, Hamada S, Jurcisin I. , et al. Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage. Br J Anaesth 2014; 112 (03) 514-520
    CrossrefPubMedGoogle Scholar
  • 54 Niederdöckl J, Dempfle CE, Schönherr HR. , et al. Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors. Int J Lab Hematol 2016; 38 (04) 426-434
    CrossrefPubMedGoogle Scholar
  • 55 Sharma P, Scotland G, Cruickshank M. , et al. Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 2015; 5 (06) e007758
    CrossrefPubMedGoogle Scholar
  • 56 Oberhardt BJ, Dermott SC, Taylor M, Alkadi ZY, Abruzzini AF, Gresalfi NJ. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. Clin Chem 1991; 37 (04) 520-526
    PubMedGoogle Scholar
  • 57 Ogawa S, Tanaka KA, Nakajima Y. , et al. Fibrinogen measurements in plasma and whole blood: a performance evaluation study of the dry-hematology system. Anesth Analg 2015; 120 (01) 18-25
    CrossrefPubMedGoogle Scholar
  • 58 Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 59 Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth 2012; 26 (06) 1083-1093
    CrossrefPubMedGoogle Scholar
  • 60 Ogawa S, Szlam F, Bolliger D, Nishimura T, Chen EP, Tanaka KA. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg 2012; 115 (01) 16-21
    CrossrefPubMedGoogle Scholar
  • 61 Solomon C, Cadamuro J, Ziegler B. , et al. A comparison of fibrinogen measurement methods with fibrin clot elasticity assessed by thromboelastometry, before and after administration of fibrinogen concentrate in cardiac surgery patients. Transfusion 2011; 51 (08) 1695-1706
    CrossrefPubMedGoogle Scholar
  • 62 Solomon C, Baryshnikova E, Schlimp CJ, Schöchl H, Asmis LM, Ranucci M. FIBTEM PLUS provides an improved thromboelastometry test for measurement of fibrin-based clot quality in cardiac surgery patients. Anesth Analg 2013; 117 (05) 1054-1062
    CrossrefPubMedGoogle Scholar
  • 63 Fabbro II M, Gutsche JT, Miano TA, Augoustides JG, Patel PA. Comparison of thrombelastography-derived fibrinogen values at rewarming and following cardiopulmonary bypass in cardiac surgery patients. Anesth Analg 2016; 123 (03) 570-577
    CrossrefPubMedGoogle Scholar
  • 64 Deppe AC, Weber C, Zimmermann J. , et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 2016; 203 (02) 424-433
    CrossrefPubMedGoogle Scholar
  • 65 Ranucci M, Baryshnikova E. Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST). Br J Anaesth 2016; 116 (05) 618-623
    CrossrefPubMedGoogle Scholar
  • 66 Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106 (05) 1366-1375
    CrossrefPubMedGoogle Scholar
  • 67 Dyke C, Aronson S, Dietrich W. , et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg 2014; 147 (05) 1458-1463.e1
    CrossrefPubMedGoogle Scholar
  • 68 Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. ; Surgical and Clinical Outcome Research (SCORE) Group. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91 (01) 123-129
    CrossrefPubMedGoogle Scholar
  • 69 Avidan MS, Alcock EL, Da Fonseca J. , et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004; 92 (02) 178-186
    CrossrefPubMedGoogle Scholar
  • 70 Fassl J, Matt P, Eckstein F. , et al. Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management. J Cardiothorac Vasc Anesth 2013; 27 (06) 1181-1188
    CrossrefPubMedGoogle Scholar
  • 71 Girdauskas E, Kempfert J, Kuntze T. , et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140 (05) 1117-24.e2
    CrossrefPubMedGoogle Scholar
  • 72 Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A. ; Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015; 4 (06) e002066
    CrossrefPubMedGoogle Scholar
  • 73 Drews S, Bolliger D, Kaiser C. , et al. Prasugrel increases the need for platelet transfusions and surgical reexploration rates compared with clopidogrel in coronary artery bypass surgery. Thorac Cardiovasc Surg 2015; 63 (01) 28-35
    PubMedGoogle Scholar
  • 74 Görlinger K, Dirkmann D, Hanke AA. , et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115 (06) 1179-1191
    CrossrefPubMedGoogle Scholar
  • 75 Flechtenmacher N, Kämmerer F, Dittmer R. , et al. Clopidogrel resistance in neurovascular stenting: correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. AJNR Am J Neuroradiol 2015; 36 (10) 1953-1958
    CrossrefPubMedGoogle Scholar
  • 76 Bolliger D, Filipovic M, Matt P. , et al. Reduced aspirin responsiveness as assessed by impedance aggregometry is not associated with adverse outcome after cardiac surgery in a small low-risk cohort. Platelets 2016; 27 (03) 254-261
    CrossrefPubMedGoogle Scholar
  • 77 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138 (03) 152-163
    CrossrefPubMedGoogle Scholar
  • 78 Bolliger D, Seeberger MD, Tanaka KA. , et al. Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry. Platelets 2009; 20 (07) 458-465
    CrossrefPubMedGoogle Scholar
  • 79 Ranucci M, Baryshnikova E, Crapelli GB, Ranucci M, Meloni S, Pistuddi V. ; Clinical and Surgical Outcome Research Score Group. Electric impedance platelet aggregometry in cardiac surgery patients: a comparative study of two technologies. Platelets 2016; 27 (03) 185-190
    CrossrefPubMedGoogle Scholar
  • 80 Jakubowski JA, Payne CD, Li YG. , et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99 (02) 409-415
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Ak K, Isbir CS, Tetik S. , et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg 2009; 24 (04) 404-410
    CrossrefPubMedGoogle Scholar
  • 82 Nuttall GA, Oliver WC, Santrach PJ. , et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001; 94 (05) 773-781 , discussion 5A–6A
    CrossrefPubMedGoogle Scholar
  • 83 Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86 (04) 575-578
    CrossrefPubMedGoogle Scholar
  • 84 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88 (02) 312-319
    PubMedGoogle Scholar
  • 85 Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass?. Br J Anaesth 2003; 90 (05) 692-693
    CrossrefPubMedGoogle Scholar
  • 86 Harrison P. Platelet function analysis. Blood Rev 2005; 19 (02) 111-123
    CrossrefPubMedGoogle Scholar
  • 87 Hanke AA, Roberg K, Monaca E. , et al. Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate). Eur J Med Res 2010; 15 (05) 214-219
    PubMedGoogle Scholar
  • 88 Alström U, Granath F, Oldgren J, Ståhle E, Tydén H, Siegbahn A. Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. Thromb Res 2009; 124 (05) 572-577
    CrossrefPubMedGoogle Scholar
  • 89 Kakouros N, Kickler TS, Laws KM, Rade JJ. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost 2013; 11 (10) 1814-1822
    CrossrefPubMedGoogle Scholar
  • 90 Carroll RC, Chavez JJ, Snider CC, Meyer DS, Muenchen RA. Correlation of perioperative platelet function and coagulation tests with bleeding after cardiopulmonary bypass surgery. J Lab Clin Med 2006; 147 (04) 197-204
    CrossrefPubMedGoogle Scholar
  • 91 Mahla E, Suarez TA, Bliden KP. , et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5 (02) 261-269
    CrossrefPubMedGoogle Scholar